Cargando…
Low-dose oral cyclophosphamide therapy reduces atherosclerosis progression by decreasing inflammatory cells in a murine model of atherosclerosis
BACKGROUND: Atherosclerosis is a chronic inflammatory disease responsible for most cases of heart disease and stroke in Western countries. The cytotoxic drug cyclophosphamide (CPA) can modulate immune functions, and it has therefore been used to treat patients with autoimmune diseases. Extension of...
Autores principales: | Sato-Okabayashi, Yayoi, Isoda, Kikuo, Heissig, Beate, Kadoguchi, Tomoyasu, Akita, Koji, Kitamura, Kenichi, Shimada, Kazunori, Hattori, Koichi, Daida, Hiroyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300380/ https://www.ncbi.nlm.nih.gov/pubmed/32577494 http://dx.doi.org/10.1016/j.ijcha.2020.100529 |
Ejemplares similares
-
An Interleukin-6 Receptor Antibody Suppresses Atherosclerosis in Atherogenic Mice
por: Akita, Koji, et al.
Publicado: (2017) -
Lack of IκBNS promotes cholate-containing high-fat diet-induced inflammation and atherogenesis in low-density lipoprotein (LDL) receptor-deficient mice
por: Kitamura, Kenichi, et al.
Publicado: (2019) -
Possible Role of NADPH Oxidase 4 in Angiotensin II-Induced Muscle Wasting in Mice
por: Kadoguchi, Tomoyasu, et al.
Publicado: (2018) -
Voluntary exercise and cardiac remodeling in a myocardial infarction model
por: Shahi, Hamad Al, et al.
Publicado: (2020) -
Dipeptidyl‐Peptidase‐4 Inhibitor, Alogliptin, Attenuates Arterial Inflammation and Neointimal Formation After Injury in Low‐Density Lipoprotein (LDL) Receptor‐Deficient Mice
por: Akita, Koji, et al.
Publicado: (2015)